Get the Stockscreener App
1.68
1.18%
-0.02
Senti Biosciences Inc stock is traded at $1.68, with a volume of 69,522.
It is down -1.18% in the last 24 hours and down -23.29% over the past month.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
See More
Previous Close:
$1.70
Open:
$1.73
24h Volume:
69,522
Relative Volume:
0.26
Market Cap:
$43.82M
Revenue:
$1.79M
Net Income/Loss:
$-70.90M
P/E Ratio:
-0.1081
EPS:
-15.54
Net Cash Flow:
$-34.95M
1W Performance:
-12.95%
1M Performance:
-23.29%
6M Performance:
-61.47%
1Y Performance:
-22.22%
1-Day Range:
$1.62
$1.73
1-Week Range:
$1.62
$1.91
52-Week Range:
$1.5201
$16.94
Senti Biosciences Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Inc
Sector
Industry
Phone
(650) 382-3281
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
1.68 | 44.34M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Laidlaw | Buy |
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Stock (SNTI) Latest News
What makes Senti Biosciences Inc. stock price move sharplyLoss Limitation Strategy Based on Analysis - Newser
What catalysts could drive Senti Biosciences Inc. stock higher in 2025Value Investing Opportunities For 2025 - jammulinksnews.com
How many analysts rate Senti Biosciences Inc. as a “Buy”AI Powered Ideas With High Returns - jammulinksnews.com
How Senti Biosciences Inc. stock performs during market volatilityFree Earnings Play Trade Plan With Alerts - Newser
Long term hold vs stop loss in Senti Biosciences Inc.Daily Technical Forecast for Quick Gains - Newser
Why Senti Biosciences Inc. stock attracts strong analyst attentionReal Stock Picks With Setup Verification - Newser
What is Senti Biosciences Inc. company’s growth strategyEarnings Report Guidance For Smart Trading - jammulinksnews.com
Is it too late to sell Senti Biosciences Inc.Free Proven Entry Plan With Low Risk Trade - Newser
Is Senti Biosciences Inc. stock overhyped or has real potentialFree Breakout Confirmation With Entry Tracker - Newser
Senti Biosciences Inc. Recovers — But Is It SustainableTrade Scanner With Buy Zone Alerts Flagged - metal.it
Using Ichimoku Cloud for Senti Biosciences Inc. technicalsMarket Stability and Long-Term Growth Outlook - Newser
Senti Biosciences Inc. Chart Enters High Volatility ZoneLow Risk Swing Trade Opportunities Identified - metal.it
Pattern Scan Adds Senti Biosciences Inc. to WatchlistReal Trader Watchlist of Hot Stocks Released - metal.it
How does Senti Biosciences Inc. generate profit in a changing economyPhenomenal returns - jammulinksnews.com
How does Senti Biosciences Inc. compare to its industry peersFree Consultation - jammulinksnews.com
How Efficient Is Senti Biosciences Inc. at Controlling Operating CostsBuy List With Technical Entry Triggers - Newser
Full technical analysis of Senti Biosciences Inc. stock Trade Safety Matrix for Conservative Traders - Newser
Is Senti Biosciences Inc. stock entering bullish territory Free Capital Growth With Controlled Risk Picks - Newser
Is Senti Biosciences Inc. stock overvalued or undervaluedAchieve breakthrough performance in the market - jammulinksnews.com
Senti Biosciences Inc. Earnings Report Breakdown: What Investors Should KnowROI Driven Alerts - Newser
Is Senti Biosciences Inc. Stock Overbought or Oversold RSI Indicator AnalysisTriple Digit Return Forecasts - Newser
Competitive Positioning of Senti Biosciences Inc.: Is It Leading or LaggingRisk Adjusted Stock Signals - Newser
What analysts say about Senti Biosciences Inc. stockPowerful profit generation - PrintWeekIndia
What drives Senti Biosciences Inc. stock priceHigh-yield trading alerts - Autocar Professional
Can Senti Biosciences Inc. stock recover from recent declineUnstoppable trading performance - jammulinksnews.com
Is Senti Biosciences Inc. a good long term investmentAccelerated capital growth - jammulinksnews.com
Senti Biosciences Inc. Stock Analysis and ForecastFree Consultation - jammulinksnews.com
Senti Biosciences Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - Yahoo Finance
Quipt Home Medical: Top 10 Undervalued Medical Distribution Industry Stocks (QIPT) - The Globe and Mail
Solid Biosciences Inc. shares rise 3.29% premarket after Senti Bio's presentation at BioScience Forum. - AInvest
Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum - The Manila Times
Senti Biosciences Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Senti Biosciences Inc Stock (SNTI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lu Timothy K | CEO |
Feb 06 '25 |
Sale |
4.36 |
545 |
2,376 |
82,082 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 04 '25 |
Sale |
4.07 |
1,297 |
5,279 |
8,803 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 06 '25 |
Sale |
4.37 |
182 |
795 |
8,621 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):